Comparison of two cross-bridged macrocyclic chelators for the evaluation of 64Cu-labeled-LLP2A, a peptidomimetic ligand targeting VLA-4-positive tumors

Nuclear Medicine and Biology

Volumn 40, Issue 2, 2013, Pages 245-251

  Jiang, Majiong ^a,c   Ferdani, Riccardo ^b   Shokeen, Monica ^b   Anderson, Carolyn J ^a,b,c  

^a WASHINGTON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Copper 64; PET imaging; VLA 4

Indexed keywords

11 BIS(CARBOXYMETHYL) 1,4,8,11 TETRAAZA BICYCLO[6.6.2]HEXADECANE LLP2A C 64; CB TE1A1P LLP2A C 64; CHELATING AGENT; COPPER 64; MACROCYCLIC COMPOUND; METHANEPHOSPHONIC ACID; PEPTIDOMIMETIC AGENT; PHOSPHONIC ACID DERIVATIVE; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CHEMICAL BOND; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG BINDING SITE; DRUG DISTRIBUTION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TUMOR LEVEL; ISOTOPE LABELING; MEDICAL PARAMETERS; MELANOMA CELL; MOUSE; NEOPLASM; NONHUMAN; PROTEIN BINDING; PROTEIN TARGETING; TUMOR BLOOD RATIO; TUMOR MUSCLE RATIO;

ANIMALS; CHELATING AGENTS; COPPER RADIOISOTOPES; DIPEPTIDES; INTEGRIN ALPHA4BETA1; LIGANDS; MACROCYCLIC COMPOUNDS; MELANOMA, EXPERIMENTAL; MICE; PEPTIDOMIMETICS; PHENYLUREA COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOCHEMISTRY;

EID: 84872931215     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2012.10.010     Document Type: Article

References (25)

1. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110:673-677.
2. Gupta M.K., Qin R. Mechanism and its regulation of tumor-induced angiogenesis. World J Gastroenterol 2003, 9:1144-1155.
3. Holzmann B., Gosslar U., Bittner M. α4 integrins and tumor metastasis. Curr Top Microbiol Immunol 1998, 231:125-141.
4. 1integrin prevents apoptosis in B cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax. Leukemia 1999, 13:266-274.
5. 4 cytoplasmic domain-specific activation of c-Src. Mol Cell Biol 2005, 25:9700-9712.
6. Fischman A.J., Babich J.W., Strauss H.W. A ticket to ride: peptide radiopharmaceuticals. J Nucl Med 1993, 34:2253-2263.
7. Okarvi S.M. Peptide-based radiopharmaceuticals: future tools for diagnostic imaging of cancers and other diseases. Med Res Rev 2004, 24:357-397.
8. 1integrin for in vivo tumor imaging. Nat Chem Biol 2006, 2:381-389.
9. 1 integrin: comparative pharmacokinetics for imaging and therapy of lymphoid malignancies. J Nucl Med 2009, 50:625-634.
10. 1 integrin) in the premetastatic niche. J Nucl Med 2012, 53:1-8.
11. Sprague J.E., Peng Y., Sun X., Weisman G.R., Wong E.H., Achilefu S., et al. Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclicchelator. Clin Cancer Res 2004, 10:8674-8682.
12. Boswell C.A., Sun X., Niu W., Weisman G.R., Wong E.H., Rheingold A.L., et al. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem 2004, 47:1465-1474.
13. Stigers D.J., Ferdani R., Weisman G.R., Wong E.H., Anderson C.J., Golen J.A., et al. A new phosphonatependant-armed cross-bridged tetraaminechelator accelerates copper (II) binding for radiopharmaceutical applications. Dalton Trans 2010, 39:1699-1701.
14. 64Cu-labeling and biological evaluation of cross-bridged cyclamchelators with phosphonate pendant arms. Dalton Trans 2012, 41:1938-1950.
15. Weisman G.R., Rogers M.E., Wong E.H., Jasinski J.P., Paight E.S. Cross-bridged cyclam: protonation and Li+ complexation in a diamond-lattice cleft. J Am Chem Soc 1990, 112:8604-8605.
16. Luster A.D., Alon R., Andrian U.H. Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol 2005, 6:1182-1190.
17. Miyake K., Hasunuma Y., Yagita H., Kimoto M. Requirement for VLA-4 and VLA-5 integrins in lymphoma cells binding to and migration beneath stromal cells in culture. J Cell Biol 1992, 119:653-662.
18. Juneja H.S., Schmalsteig F.C., Lee S., Chen J. Vascular cell adhesion molecule-1 and VLA-4 are obligatory adhesion proteins in the heterotypic adherence between human leukemia/lymphoma cells and marrow stromal cells. Exp Hematol 1993, 21:444-450.
19. Schadendorf D., Gawlik C., Haney U., Ostmeier H., Suter L., Czarnetzki B.M. Tumour progression and metastatic behaviour in vivo correlates with integrin expression on melanocytic tumours. J Pathol 1993, 170:429-434.
20. Yoneda T. Cellular and molecular basis of preferential metastasis of breast cancer to bone. J Orthop Sci 2000, 5:75-81.
21. Lapidot T., Dar A., Kollet O. How do stem cells find their way home?. Blood 2005, 106:1901-1910.
22. Kuphal S., Bauer R., Bosserhoff A.K. Integrin signaling in malignant melanoma. Cancer Metastasis Rev 2005, 24:195-222.
23. 3-Octreotate using a phosphonic acid-based cross-bridged macrocyclic chelator. Bioconjugate Chem. 2012, 23:1470-1477.
24. Jones-Wilson T.M., Deal K.A., Anderson C.J., McCarthy D.W., Kovacs Z., Motekaitis R.J., et al. The in vivo behavior of copper-64-labeled azamacrocyclic complexes. Nucl Med Biol 1998, 25:523-530.
25. 111In-DTPA-conjugated peptides. Nucl Med Biol 2001, 28:761-768.